x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012056
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IP, IF |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human GCKR protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | GCKR |
| UniProt No. | Q14397 |
| Gene ID | 2646 |
| Gene Description | Glucokinase regulatory protein regulates the activity and localization of glucokinase, an important metabolic regulator of glucose uptake, glycogen synthesis, and glucose production in hepatocytes. GKRP plays a key role in glucose homeostasis as it inhibits glucokinase activity and sequesters this metabolic enzyme in hepatocyte nuclei; in response to changes in glucose concentration, GCKR promotes the release of glucokinase into the cytoplasm. During conditions of low blood glucose levels, GCKR binds to fructose-6-phosphate, which leads to GCKR binding to glucokinase and the subsequent nuclear localization and inactivation of glucokinase. After feeding, GCKR binds fructose-1-phosphate, which disrupts the interaction between GCKR and glucokinase and releases active glucokinase to cytoplasm. Polymorphisms in the corresponding GCKR gene are associated with atypical plasma triglyceride levels, fasting glucose and insulin levels, and glucokinase activity. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
